JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB265910

Human NEK6 knockout HeLa cell line

Be the first to review this product! Submit a review

|

(0 Publication)

NEK6 KO cell line available to order. KO validated by Western blot. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 3 and 304 bp deletion in exon 3 and Insertion of the selection cassette in exon 3.

View Alternative Names

Highly similar to cell cycle protein kinase CDC5/MSD2, NEK6_HUMAN, NIMA (Never In Mitosis Gene A) Related Kinase 6, Never in mitosis A-related kinase 6, NimA-related protein kinase 6, Protein kinase SID6-1512, Putative serine threonine protein kinase, SID6 1512, Serine/threonine-protein kinase Nek6

5 Images
Western blot - Human NEK6 knockout HeLa cell line (AB265910)
  • WB

Lab

Western blot - Human NEK6 knockout HeLa cell line (AB265910)

Lanes 1-3 : Merged signal (red and green). Green - ab109177 observed at 36 kDa. Red - loading control ab7291 observed at 50 kDa.

ab109177 Anti-NEK6 antibody [EPR5282] was shown to specifically react with NEK6 in wild-type HeLa cells. Loss of signal was observed when knockout cell line ab265910 (knockout cell lysate ab258072) was used. Wild-type and NEK6 knockout samples were subjected to SDS-PAGE. ab109177 and Anti-alpha Tubulin antibody [DM1A] - Loading Control (ab7291) were incubated overnight at 4°C at 1 in 1000 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye®800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye®680RD) preadsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.

Lanes 1 - 3:

Anti-VEGF Receptor 3 antibody (<a href='/en-us/products/unavailable/vegf-receptor-3-antibody-ab10977'>ab10977</a>) at 1/1000 dilution

Lanes 1 - 3:

Western blot - Anti-NEK6 antibody [EPR5282] (<a href='/en-us/products/primary-antibodies/nek6-antibody-epr5282-ab109177'>ab109177</a>) at 1/1000 dilution

Lane 1:

Wild-type HeLa cell lysate at 20 µg

Lane 2:

NEK6 knockout HeLa cell lysate at 20 µg

Lane 2:

Western blot - Human NEK6 knockout HeLa cell line (ab265910)

Lane 3:

HepG2 cell lysate at 20 µg

Secondary

All lanes:

Western blot - Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-irdye-800cw-preadsorbed-ab216773'>ab216773</a>) at 1/10000 dilution

Predicted band size: 15 kDa,36 kDa,54 kDa,66 kDa,88 kDa,92 kDa

Observed band size: 15 kDa,36 kDa,56 kDa,88 kDa,92 kDa

false

Western blot - Human NEK6 knockout HeLa cell line (AB265910)
  • WB

Lab

Western blot - Human NEK6 knockout HeLa cell line (AB265910)

Lanes 1-3 : Merged signal (red and green). Green - ab133494 observed at 36 kDa. Red - loading control ab7291 observed at 50 kDa.

ab133494 Anti-NEK6 antibody [EPR5283] was shown to specifically react with NEK6 in wild-type HeLa cells. Loss of signal was observed when knockout cell line ab265910 (knockout cell lysate ab258072) was used. Wild-type and NEK6 knockout samples were subjected to SDS-PAGE. ab133494 and Anti-alpha Tubulin antibody [DM1A] - Loading Control (ab7291) were incubated overnight at 4°C at 1 in 1000 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.

All lanes:

Western blot - Anti-NEK6 antibody [EPR5283] (<a href='/en-us/products/primary-antibodies/nek6-antibody-epr5283-ab133494'>ab133494</a>) at 1/1000 dilution

Lane 1:

Wild-type HeLa cell lysate at 20 µg

Lane 2:

NEK6 knockout HeLa cell lysate at 20 µg

Lane 2:

Western blot - Human NEK6 knockout HeLa cell line (ab265910)

Lane 3:

HepG2 cell lysate at 20 µg

Secondary

All lanes:

Western blot - Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-irdye-800cw-preadsorbed-ab216773'>ab216773</a>) at 1/10000 dilution

Predicted band size: 36 kDa,53 kDa

Observed band size: 36 kDa,53 kDa

false

Sanger Sequencing - Human NEK6 knockout HeLa cell line (AB265910)
  • Sanger seq

Unknown

Sanger Sequencing - Human NEK6 knockout HeLa cell line (AB265910)

Allele-2 : 1 bp insertion in exon 3.

Sanger Sequencing - Human NEK6 knockout HeLa cell line (AB265910)
  • Sanger seq

Unknown

Sanger Sequencing - Human NEK6 knockout HeLa cell line (AB265910)

Allele-1 : 304 bp deletion in exon 3.

Sanger Sequencing - Human NEK6 knockout HeLa cell line (AB265910)
  • Sanger seq

Unknown

Sanger Sequencing - Human NEK6 knockout HeLa cell line (AB265910)

Allele-3 : Insertion of the selection cassette in exon 3.

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Sanger Sequencing,Western blot

Mutation description

Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 3 and 304 bp deletion in exon 3 and Insertion of the selection cassette in exon 3

Disease

Adenocarcinoma

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "WB": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

Product details

Recommended control: Human wild-type HeLa cell line (ab255928). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265910-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265910 Human NEK6 knockout HeLa cell line", "number":"AB265910-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265910-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265910 Human NEK6 knockout HeLa cell line", "number":"AB265910-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
NEK6
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing, Western blot
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The protein NIMA-related kinase 6 (NEK6) acts as a serine/threonine kinase involved in cell cycle regulation. It is also known as Never In Mitosis Gene A-related kinase 6. NEK6 has a molecular mass of approximately 40 kDa. Cells mainly express NEK6 in proliferating tissues. Its activity is dependent on phosphorylation by other kinases which allows NEK6 to proceed with mitosis by controlling different cellular processes.
Biological function summary

NEK6 plays a critical role in mitotic cell division by promoting progression through the G2/M phase of the cell cycle. Although NEK6 does not form part of a classical protein complex it does interact with various substrates to ensure successful mitosis. It stabilizes microtubule organization ensuring proper chromosomal segregation and cell cycle progression by facilitating microtubule nucleation and stability.

Pathways

NEK6 contributes to cell cycle control and microtubule dynamics being important within the context of the DNA damage response and repair pathways. NEK6 is associated with the p53 signaling pathway where it functions alongside related proteins such as NEK7. These kinases coordinate cellular responses to stress and damage ultimately maintaining genomic stability and preventing aberrant cell division.

NEK6 has been linked to oncogenesis especially in various types of cancer. Overexpression or dysregulation of NEK6 can promote tumor growth with studies showing its involvement in conditions such as breast cancer. NEK6 activity parallels oncogenic signals often interacting with proteins like p53 whose inactivation contributes to tumorigenesis. Understanding NEK6's role in these pathways may offer novel therapeutic targets for cancer treatment.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com